Human chorionic gonadotropin as a target for cancer vaccines (Review)

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 7-17

  Triozzi, Pierre L ^a,b   Stevens, Vernon C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer vaccines; Human chorionic gonadotropin

Indexed keywords

CANCER VACCINE; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; DIPHTHERIA TOXIN; HORMONE; HUMAN CHORIONIC GONADOTROPIN DIPHTHERIA TOXIN FRAGMENT A; HUMAN CHORIONIC GONADOTROPIN-DIPHTHERIA TOXIN FRAGMENT A; PEPTIDE FRAGMENT; RECOMBINANT VACCINE; TUMOR PROTEIN;

ALLELE; ANIMAL; ANTIBODY SPECIFICITY; CLINICAL TRIAL; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOCONTRACEPTION; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NEOPLASM; PAPIO; PHYSIOLOGY; PREGNANCY; RABBIT; REVIEW; TH1 CELL; TH2 CELL;

ALLELES; ANIMALS; CANCER VACCINES; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CLINICAL TRIALS; CONTRACEPTION, IMMUNOLOGIC; DIPHTHERIA TOXIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES, ECTOPIC; HUMANS; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; PAPIO; PEPTIDE FRAGMENTS; PREGNANCY; RABBITS; TH1 CELLS; TH2 CELLS; VACCINES, SYNTHETIC;

EID: 0032614547     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Nestle FO, Alhagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
2. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wundrlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
3. Van den Eynde BJ and Boon T: Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27: 81-86, 1997.
4. Bellet D, Lazar V, Bieche I, Paradis V, Giovangrandi Y, Paterlini P, Lidereau R, Bedosaa P, Bidart JM and Vidaud M: Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin β genes normally transcribed in trophoblastic cells. Cancer Res 57: 516-523, 1997.
5. Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, Morgan FJ and Isaacs NW: Crystal structure of human chorionic gonadotropin. Nature 369: 455-461, 1994.
6. Hoermann R, Spoetl G, Moncayo R and Mann K: Evidence for the presence of human chorionic gonadotropin (hCG) and free β-subunit of hCG in the human pituitary. J Clin Endocrinol Metab 71: 179-186, 1990.
7. Lazar V, Diez SG, Laurent A, Giovangrandi Y, Radvanyi F, Chopin D, Bidart JM, Bellet D and Vidaud M: Expression of human chorionic gonadotropin β subunit genes in superficial and invasive bladder carcinomas. Cancer Res 55: 3735-3738, 1995.
8. Lojun S, Bao S, Lei ZM and Rao CV: Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. Biol Reprod 57: 1202-1210, 1997.
9. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbaher S and Berger P: Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35: 212-220, 1998.
10. Elliott MM, Kardana A, Lustbader JW and Cole LA: Carbohydrate and peptide structure of the alpha and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 7: 15-32, 1997.
11. Braunstein GD: Placental proteins as tumor markers. In: Immunodiagnosis of Cancer. Herberman RB and Mercer DW (eds). Marcel Dekker. Inc., New York, pp673-701, 1990.
12. Alfthan H, Haglund C, Roberts P and Stenman U-H: Elevation of free β subunit of human choriogonadotropin and core β fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 52: 4628-4633, 1992.
13. Marcillac I, Troalen F, Bidart J-M, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz J-P, Lhomme C, Rougier P, Duvillard P, Prade M, Lugange P-M, Richard F, Poynard T, Bohuon C, Wands J and Bellet D: Free human chorionic gonadotropin β subunit in gonadal and nongonadal neoplasms. Cancer Res 52: 3901-3907, 1992.
14. Acevedo HF, Krichevsky A, Campbell-Acevedo, Galyon JC, Buffo MJ and Hartsock RJ: Expression of membrane-associated human choriosonadotropin, its subunits and fragments by cultured human cancer cells. Cancer 69: 1829-1842, 1992.
15. Yakeisha Y, Masaki M and Munetomo E: Distribution of β-human chorionic gonadotropin-positive cells in noncancerous gastric mucosa and in malignant gastric tumors. Cancer 66: 695-701, 1990.
16. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI and Livingston PO: Expression of potential target antigens for immunotherapy of primary and metastatic prostate cancers. Clin Cancer Res 4: 295-302, 1998.
17. Triozzi PL, Gochnour D, Martin EW, Aldrich W, Powell J, Kim JA, Young DC and Lombardi J: Clinical and immunologic effects of a synthetic β-human chorionic gonadotropin vaccine. Int J Oncol 5: 1447-1454, 1994.
18. Kim SJ, Namkoong SE, Lee OW, Jung UK, Kang BC and Park JS: Response of human chorionic gonadtrophin to luteinizing hormone-releasing hormone stimulation in the culture media of normal human placenta, choriocarcinoma cell lines, and in the serum of patients with aestational trophoblastic disease. Placenta 8: 257-264, 1987.
19. Anderson B, Milsted A, Kennedy G and Nilson JH: Cyclic AMP phorbol esters interact synergistically to regulate expression of chorionic gonadotrophin genes. J Biol Chem 263: 15578-15584, 1988.
20. Ritvos O, Jolkunen J, Pekonen F, Stenman UH and Ranta T: Epidermal growth factor but not insulin-like growth factor-1 potentiates adenoside 3′5′-monophosphate-mediated chorionic aonadotropin secretion by cultured human choriocarcinoma cells. Endocrinology 123: 859-865, 1988.
21. Iles RK and Chard T: Enhancement of ectopic β-human chorionic gonadotrophin expression by interferon-α. J Endocrinol 123: 501-507, 1989.
22. Agnantis NJ, Patra F, Khaldi L and Filis ST: Immunohistochemcial expression of subunit β HCG in breast cancer. Eur J Gynaecol Oncol 13: 461-466, 1992.
23. Rodway MR and Rao Ch V: A novel perspective on the role of human chorionic gonadotropin during pregnancy and in gestational trophoblastic disease. Early Pregnancy 1: 176-187, 1995.
24. Leutz A and Graf T: Relationships between oncogenes and growth control. In: Peptide Growth Factors and their Receptors. Vol. II. Sporn MB and Roberts AB (eds). Springer-Verlag, Berlin, pp655-703, 1990.
25. Rivera RT, Paison SG and Wong DT, et al: Loss of tumorigenic potential by human lung tumor cells in the presence of nonsense RNA specific to the ectopically synthesized alpha subunit of human chorionic gonadotropin. J Cell Biol 108: 2423-2434, 1989.
26. Kumar S, Talwar GP and Biswas DK: Necrosis and inhibition of growth of human lung tumor by anti-α-human chorionic gonadotropin antibody. J Natl Cancer Inst 84: 42-47, 1992.
27. Gillott DJ, Iles RK and Chard T: The effects of beta-human chorionic gonadotrophin on the in vitro growth of bladder cancer cells lines. Br J Cancer 73: 323-326, 1996.
28. Lin J, Lei ZM, Lojun S, Rao CV, Satyaswaroop PG and Day TG: Increased expression of luteinizing hormone/human chorionic gonadotopin receptor gene in human endometrial carcinomas. J Clin Endorcinol Metab 79: 1483-1491, 1994.
29. Tao Y-X, Bao S, Ackermann DM, Lei ZM and Rao CV: Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostate hyperplasia and in prostate carcinoma. Biol Reprod 56: 67-72, 1997.
30. Krown SE: Kaposi's sarcoma: what's human chorionic gonadotropin got to do with it? N Engl J Med 335: 1309-1310, 1996.
31. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D and Breckwoldt M: Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells; important in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80: 1967-1971, 1995.
32. Hostetter RB, Augustus LB, Mankarious R, Chi KF, Fan D, Toth C, Thoas P and Jessup JM: Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 82: 380-385, 1990.
33. Acevedo HF and Harsock RJ: Metastatic phenotype correlates with high expression of membrane-associated complete β-human chorionic gonadotropin in vivo. Cancer 78: 2388-2399, 1996.
34. Yagel S, Geva TE, Solomon H, Shimonovitz S, Reich R, Finci-Yeheskel Z, Mayer M and Milwidsky A: High levels of human chorionic gonadotropin retard first trimester trophoblast invasion in vitro by decreasing urokinase plasminogen activator and collagenase activities. J Clin Endocrinol Metab 77: 1506-1511, 1993.
35. McManus LM, Naughton NA and Martinez HA: Human chorionic gonadotropin in human neoplastic cells. Cancer Res 36: 3476-3481, 1976.
36. Strelkauska AJ, Wilson BS, Dray S and Dodson M: Inversion of levels of human T- and B-cells in early pregnancy. Nature 258: 331-332, 1975.
37. Van Rinsum J, Smets LA, van Rooy J and van Den Eunden DH: Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo oligosaccharides. Int J Cancer 38: 915-922, 1986.
38. Oliver RTD, Nouri AME, Crosby D, Iles RL, Navarette C, Martin J, Bodmer W and Festenstein H: Biological significance of beta hCG, HLA and other membrane antigen expression on bladder tumours and their relationship to tumour infiltrating lymphocytes (TIL). J Immunogenet 16: 381-390, 1989.
39. Lin J, Lojun S, Lei ZM, Wu WX, Peiner SC and Rao CV: Lymphocytes from pregnant women express human chorionic gonadotropin/luteinizing hormone receptor gene. Mol Cell Endocrinol 111: R13-R17, 1995.
40. Han T: Human chorionic gonadotropin. Its inhibitory effect on cell-mediated immunity in vivo and in vitro. Immunology 29: 509-515, 1975.
41. Beling CG and Weksler ME: Suppression of mixed lymphocyte reactivity by human chorionic sonadotrophin. Clin Exp Immunol 18: 537-541, 1974.
42. Han T: Inhibitory effect of human chorionic gonadotrophin on lymphocyte blastogenic response to mitogen, antigen and allogeneic cells. Clin Exp Immunol 18: 529-535, 1974.
43. Schafer A, Pauli G, Friedmann W and Dudenhausen JW: Human choriogonadotropin (hCG) and placental lactogen (hPL) inhibit interleukin-2 (IL-2) and increase interleukin-1β (IL-1β).-6 (IL-6) and tumor necrosis factor (TNF-α) expression in monocyte cell cultures. J Perinat Med 20: 233-240, 1992.
44. Caldwell JL, Stites DP and Fudenberg HH: Human chorionic gonadotropin: effects of crude and purified preparations on lymphocyte responses to phytohemagglutinin and allogenenic stimulation. J Immunol 115: 1249-1253, 1975.
45. Yamaguchi A, Ishida T, Nishimura G, Kumaki T, Katoh M, Kosaka T, Yonemura Y and Miyazaki I: Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. Br J Cancer 60: 382-384, 1989.
46. Campo E, Palacin A, Benasco C, Quesada E and Cardesa A: Human chorionic gonadotropin in colorectal carcinoma. An immunohistochemical study. Cancer 59: 1611-1616, 1987.
47. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P and Chard T: Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 77: 61-69, 1996.
48. Tormey DC, Waalkes TP and Simon RM: Biological marker in breast carcinoma: II Clinical correlation with human chorionic sonadotropin. Cancer 39: 2391-2396, 1977.
49. Oliver RTD, Stephenson C, Collino CE and Parkinson MC: Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer. Mol Biother 1: 43-45, 1988.
50. Martin JE, Jenkins BJ, Zuk RJ, Oliver RT and Baithun SI: Human chorionic gonadotrophin expression and histological findings as predictors of response to radiotherapy in carcinoma of the bladder. Virchows Arch 414: 273-277, 1989.
51. Braunstein GD, Vogel CI, Vaitukaitis JL and Ross GT: Ectopic production of human chorionic gonadotropin in Ugandan patients with hepatocellular carcinoma. Cancer 32: 223-226, 1973.
52. Horne CHW, Reid IN and Milne GD: Prognostic significance of inappropriate production of pregnancy protein by breast cancer. Lancet ii: 279-282, 1976.
53. Mohabeer J, Buckely CH and Fox H: An immunohistochemical study of the incidence and significance of human chorionic gonadotropin synthesis by epithelial ovarian neoplasm. Gynecol Oncol 16: 78-841983.
54. Lee AK, Rosen PO, Delillis RA, Saigo PE, Gangi MD, Groshen S, Bagin R and Wolfe HJ: Tumor marker expression of breast carcinomas and relationship to prognosis. An immunohistochemical study. Am J Clin Pathol 84: 687-696, 1985
55. Smith DJ, Evans HJ, Newman J and Chapple CR: Ectopic human chorionic gonadotrophin (HCG) production: is the detection by serum analysis of HCG of clinical relevance in transitional cell carcinoma of the bladder? Br J Urol 73: 409-412, 1994.
56. Bieche I, Lazar V, Nogues C, Poynard T, Giovangrandi Y, Bellet D, Lidereau R and Vidaud M: Prognostic value of chorionic β gene transcripts in human breast carcinoma. Clin Cancer Res 4: 671-676, 1998.
57. Bernstein L, Hanisch R, Sullivan-Halley J and Ross RK: Treatment with human chorionic gonadotropin and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 4: 437-440, 1995.
58. Russo IH, Koszalka M and Russo J: Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst 82: 1286-1289, 1990.
59. Srivastava P, Russo J and Russo IH: Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death. Carcinogenesis 18: 1799-1808, 1997.
60. You S, Tu Z-J and Kiang DT: Direct modulation of tumor suppressor connexin 26 gene by human chrorionic gonadotropin in rat mammary glands. Cancer Res 58: 1498-1502, 1998.
61. Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, Besnier JM, Hermans P, Thierry AR, Gill P and Gallo RC: Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375: 64-68, 1995.
62. Gill PS, Lunardi-Ishkandar Y, Louie S, Tulpule A, Zheng T, Espina BM, Besnier JM, Hermans P, Levine AM, Bryant JL and Gallo RC: The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 335: 1261-1269, 1996.
63. Kachra Z, Guo WX, Sairam MR and Antakly T: Low molecular weight components but not dimeric HCG inhibit growth and down-regulate AP-1 transcription factor in Kaposi's sarcoma cells. Endocrinology 138: 4038-4041, 1997.
64. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H and Bhattacharya-Chatterjee M: Immune response to the carcinoembryonic antigen in patients treated with an antiidiotype antibody vaccine. J Clin Invest 96: 334-342, 1995.
65. McAneny D, Ryan CA, Beazley RM and Kaufman HL: Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 3: 495-500, 1996.
66. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF and Old LJ: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036-1044, 1994.
67. Currie GA: Immunologic studies of trophoblasts in vitro. J Obstet Gynaecol Br Commonw 74: 841-848, 1967.
68. Morisada M, Yamaguchi H and Iizuka R: Toxic action of anti hCG antibody to human trophoblast. Int J Fertil 17: 65-71, 1972.
69. Hillman GG, Younes E, Visscher D, Ali E, Lam J S, Montecillo E, Pontes JE, Haas GP and Puri RK: Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma mode. Cell Immunol 160: 257-263, 1995.
70. Nakashima Y, Mita S, Takatsu K and Ogawa M: Interleukin-5 induces tumor suppression by peritoneal exudate cells in mice. Cancer Immunol Immunother 37: 227-232, 1993.
71. Housseau F, Rouas-Freiss N, Benifla J-L, Marcillac I, Roy M, Troalen F, Fernandez H, Prapotnich D, Valencien G, Bougaran J, Cottu P, Culine S, Droz J-P, Bidart J-M and Bellet D: Reaction of peripheral blood lymphocytes to the human chorionic gonadotropin β sub-unit in patients with productive tumors. Int J Cancer 63: 633-638, 1995.
72. Kellen JA, Kolin A and Acevedo HF: Effects of antibodies to choriogonadotropin in malignant growth. I Rat 3230 AC mammary adenocarcinoma. Cancer 49: 2300-2304, 1982.
73. Kellen JA, Kolin A, Mirakian A and Acevedo HF: Effects of antibodies to choriogonadotropin in malignant growth. II. Solid transplantable rat tumors. Cancer Immunol Immunother 13: 2-4, 1982.
74. Acevedo HF, Raikow RB, Powell JE and Stevens VC: Effects of immunization against human choriogonadotropin in the growth of transplanted Lewis lung carcinoma and spontaneous mammary adenocarcinoma in mice. Cancer Detect Prev 1 (Suppl.): 447-487, 1987.
75. Geissler M, Wands G, Gesien A, De la Monte S, Bellet D and Wands JR: Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest 76: 859-871, 1997
76. Leigh SE and Stewart F: Partial cDNA sequence for the donkey chorionic gonadotrophin-beta subunit suggests evolution from an ancestral LH-beta gene. J Mol Endocrinol 4: 143-150, 1990.
77. Stevens VC: Progress in the development of human chorionic aonadotropin antifertility vaccines. Am J Reprod Immunol 35: 148-155, 1996.
78. Jackson AM, Klonisch T, Lapthorn AJ, Berger P, Isaacs NW, Delves PJ, Lund T and Roitt IM: Identification and selective destruction of shared epitopes in human chorionic gonadotropin beta subunit. J Reprod Immunol 31: 21-36, 1996.
79. Pillai D, Dixit A, Alok D and Garg LC: Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in Escherichia coli and its immunogenicity. FEBS Lett 387: 23-26, 1996.
80. Baulard A, Kremer L, Supply P, Vidaud D, Bidart JM, Bellet D and Locht C: A new series of mycobacterial expression vectors for the development of live recombinant vaccines. Gene 176: 149-154, 1996.
81. Mukhopadhyay A, Bhatia PK and Majumdar SS: Preliminary studies with recombinant chorionic gonadotropin b-subunit produced in Escherichia coli for use as an antigen in a birth control vaccine. Am J Reprod Immunol 39: 172-182, 1998.
82. Talwar GP, Singh O, Gupta SK, Hasnain SE, Pal R, Majumdar SS, Vrati S, Mukhopadhay A, Srinivasan J, Deshmukh U, Ganga S, Mandokhot A and Gupta A: The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine. Am J Reprod Immunol 37: 153-160, 1997.
83. Singh O, Rao LV, Gaur A, Sharma NC, Alam A and Talwar GP: Antibody response and characteristics of antibodies in women immunized with three contraceptive vaccines including antibodies against human chorionic gonadotropin. Ferti Steril 52: 739-744, 1989.
84. Lee AC, Powell JE, Tregear GW, Niall HD and Stevens VC: A method for the preparation β-hCG COOH peptide-carrier conjugates of predictable composition. Mol Immunol 17: 749-756, 1980.
85. Stevens VC, Powell JE, Lee AC and Griffin PD: Anti-fertility effects from immunization of female baboons with C-terminal peptides of human chorionic gonadotrophin. Fertil Steril 36: 98-105, 1981.
86. Stevens VC, Cinader B, Powell JE, Lee AC and Koh SW: Preparation and formulation of an HCG anti-fertility vaccine: selection of an adjuvant and vehicle. Am J Reprod Immunol 6: 315-321, 1981.
87. Jones WR, Judd SJ, Ing RMY, Powell J, Bradley J, Denhom EH, Mueller VW, Griffin PD and Stevens VC: Phase I clinical trial of a world health organization birth control vaccine. Lancet i: 1295-1298, 1988.
88. Powell JE, Lee AC, Tregar SW, Niall HD and Stevens VC: Characteristics of antibodies raised to carboxy-terminal peptides of bhCG subunit. J Reprod Immunol 2: 1-13, 1980.
89. Triozzi PL, Stevens VC, Aldrich W, Poweli J, Todd CW and Newman MJ: Effects of a β-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin Cancer Res 3: 2355-2363, 1997.
90. McCune CS, O'Donnell RW, Mariquis DM and Sahasrabudhe DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32: 62-66, 1990.
91. Berd D, Maguire HC Jr and Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572-2577, 1986.
92. Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M and Bystryn J-C: Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res 51: 3643-3647, 1991.
93. Todd CW, Pozzi LM, Guarnaccia JR, Balasubramanian M, Henk WG, Younger LE and Newman MJ: Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 15: 564-570, 1997.
94. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G and Stevenson L: Active-specific immunotherapy for melanoma. J Clin Oncol 8: 856-869, 1990.
95. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ and Marciani D: Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12: 1275-1280, 1994.
96. Howerton DA, Hunter RL, Ziegler HK and Check IJ: Induction of macrophage la expression in vivo by a synthetic block copolymer, L81. J Immunol 144: 1578-1584, 1990.
97. Phillips NC, Moras ML, Chedid L, Lefrancier P and Bernard JM: Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 45: 128-134, 1985.
98. Stevens VC: Future perspectives for vaccine development. Scand J Immunol Suppl 11: 137-143, 1992.